Name | No. | For Patients with | Purpose |
---|---|---|---|
GIV-IN PV Trial | 24-99 | JAK2V617F-positive high-risk Polycythemia Vera patients |
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high-risk polycythemia vera patients. |
DSSG Group: Lymphoma & blood cancers
CA057-001 (SUCCESSOR-1)
Name | No. | For Patients with | Purpose |
---|---|---|---|
CA057-001 (SUCCESSOR-1) | 23-20 | Relapsed or refractory multiple myeloma |
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure. |
MOSAICC
Name | No. | For Patients with | Purpose |
---|---|---|---|
MOSAICC | 19-41 | Myeloproliferative neoplasms and non-blood relative/friend controls. |
The MOSAICC study (MyelOproliferative neoplasmS: An In-depth Case-Control) is a UK-wide case-control study that aims to identify what causes MPNs and assess the quality of life and unmet needs of those who suffer from these conditions. |
Beigene 311-308 / MAHOGANY
Name | No. | For Patients with | Purpose |
---|---|---|---|
Beigene 311-308 / MAHOGANY | 24-30 | Relapsed/Refractory Follicular or Marginal Zone Lymphoma |
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria. |
BD – Bone Marrow/Blood
Name | No. | For Patients with | Purpose | |
---|---|---|---|---|
BD – Bone Marrow/Blood | Healthy Volunteers for Research and Development Purpose |
|
firmMIND INCMOR0208-305
Name | No. | For Patients with | Purpose | |
---|---|---|---|---|
firmMIND INCMOR0208-305 | 24-05 | Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
LOXO-BTK-20022
Name | No. | For Patients with | Purpose | |
---|---|---|---|---|
LOXO-BTK-20022 | 21-44 | Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|